Skip to content

Study · Randomized controlled trial · n = 14 · 2006

4 results

Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study.

de Lange J, van den Akker HP, Veldhuijzen van Zanten GO, Engelshove HA, van den Berg H, Klip H

International journal of oral and maxillofacial surgery10 Jul 2006Cited by 48 (Europe PMC)

PMID16829031 (opens in a new tab)DOI10.1016/j.ijom.2006.03.030 (opens in a new tab)PepBankPUB-16829031
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In jaw granuloma, proportions with tumour reduction of at least 10% did not differ between initial calcitonin and placebo groups at three assessments.

    In plain wordsIn jaw granuloma, proportions with tumour shrinkage of at least 10% did not differ between initial calcitonin and placebo groups.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeTumour reduction responder proportion
    Study

    n = 14

    Comparator
    Initial placebo group
    Outcome group
    Tumor growth · Musculoskeletal
    Studied dose
    200 IU/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    The chi(2)-test was used to compare the proportion of patients with a tumour reduction >/=10% of the pretreatment measurement between the 2 populations at the 3 timepoints: no differences were observed between the placebo group and the calcitonin group.
    3 context sentences
    Summary · context
    In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years.
    Summary · context
    Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day.
    Summary · context
    The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year.
  2. 02HumanNon-randomized trialEfficacy outcome

    At 6-month follow-up after all patients received salmon calcitonin, tumour volume decreased by at least 10% in 7 patients with jaw granuloma.

    In plain wordsAfter all patients received salmon calcitonin, 7 patients with jaw granuloma had tumour shrinkage of at least 10% at 6-month follow-up.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseTumour reduction responders at follow-up
    Study

    n = 14

    Comparator
    Pretreatment
    Outcome group
    Tumor growth · Musculoskeletal
    Studied dose
    200 IU/day · intranasalAs given in this study (human).

    Measurements

    Responders
    7 patients
    6-month follow-up

    Source sentences

    Summary
    At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup.
    3 context sentences
    Summary · context
    In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years.
    Summary · context
    Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day.
    Summary · context
    The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with central giant cell granuloma treated with salmon calcitonin, complete remission was not observed.

    In plain wordsIn patients with jaw granuloma treated with salmon calcitonin, complete remission was not observed.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableComplete remission
    Study

    n = 14

    Outcome group
    Tumor growth · Musculoskeletal
    Studied dose
    200 IU/day · intranasalAs given in this study (human).

    Source sentences

    Summary
    Complete remission was not observed.
    3 context sentences
    Summary · context
    In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years.
    Summary · context
    Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day.
    Summary · context
    The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year.
  4. 04HumanNon-randomized trialEfficacy outcome

    In jaw granuloma responders after salmon calcitonin, mean tumour volume reduction was 37.9% (95% CI 31.3-44.5%) at follow-up.

    In plain wordsIn jaw granuloma responders after salmon calcitonin, mean tumour volume decreased by 37.9% from pretreatment.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseVolume reduction in responders
    Study

    n = 7

    Comparator
    Pretreatment
    Outcome group
    Tumor growth · Musculoskeletal
    Studied dose
    200 IU/day · intranasalAs given in this study (human).

    Measurements

    Mean volume reduction
    37.9%
    responders
    95% CI
    31.3 to 44.5%
    responders

    Source sentences

    Summary
    At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup.
    3 context sentences
    Summary · context
    In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years.
    Summary · context
    Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day.
    Summary · context
    The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.